Tarsus Pharmaceuticals (NASDAQ:TARS) Lowered to "Hold" Rating by Wall Street Zen

Wall Street Zen cut shares of Tarsus Pharmaceuticals (NASDAQ:TARS - Free Report) from a buy rating to a hold rating in a report released on Thursday.

Several other equities analysts have also recently issued reports on TARS. Guggenheim boosted their target price on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Jefferies Financial Group increased their price target on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. HC Wainwright reissued a "buy" rating and set a $73.00 price target on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 26th. Barclays dropped their price objective on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. Finally, The Goldman Sachs Group increased their price target on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a report on Monday, May 5th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $66.17.

Tarsus Pharmaceuticals Trading Down 1.4%

Shares of NASDAQ TARS traded down $0.60 during midday trading on Thursday, reaching $42.38. 270,632 shares of the stock were exchanged, compared to its average volume of 699,972. The stock has a market capitalization of $1.78 billion, a P/E ratio of -11.10 and a beta of 0.94. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. Tarsus Pharmaceuticals has a twelve month low of $20.08 and a twelve month high of $57.28. The company has a 50 day simple moving average of $47.60 and a 200 day simple moving average of $49.09.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.05. The firm had revenue of $78.34 million during the quarter, compared to analysts' expectations of $72.50 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. As a group, equities analysts expect that Tarsus Pharmaceuticals will post -3.17 earnings per share for the current year.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, General Counsel Bryan Wahl sold 3,341 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total transaction of $154,654.89. Following the completion of the transaction, the general counsel now owns 58,057 shares of the company's stock, valued at $2,687,458.53. The trade was a 5.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Dianne C. Whitfield sold 2,137 shares of the company's stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $50.11, for a total transaction of $107,085.07. Following the completion of the sale, the insider now directly owns 46,355 shares in the company, valued at approximately $2,322,849.05. The trade was a 4.41% decrease in their position. The disclosure for this sale can be found here. Insiders sold 32,542 shares of company stock valued at $1,581,173 in the last quarter. Company insiders own 8.25% of the company's stock.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Barclays PLC raised its holdings in shares of Tarsus Pharmaceuticals by 345.9% during the third quarter. Barclays PLC now owns 98,663 shares of the company's stock worth $3,246,000 after acquiring an additional 76,538 shares during the period. R Squared Ltd acquired a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth about $53,000. Baader Bank Aktiengesellschaft acquired a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth about $249,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Tarsus Pharmaceuticals by 10.8% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,106 shares of the company's stock worth $449,000 after buying an additional 789 shares during the last quarter. Finally, Jennison Associates LLC boosted its stake in shares of Tarsus Pharmaceuticals by 14.8% during the 4th quarter. Jennison Associates LLC now owns 2,500,132 shares of the company's stock worth $138,432,000 after buying an additional 321,552 shares during the last quarter. 90.01% of the stock is owned by institutional investors.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.